Emerging insights into the ependymoma epigenome

Ependymoma is the third most common pediatric brain tumor, yet because of the paucity of effective therapeutic interventions, 45% of patients remain incurable. Recent transcriptional and copy number profiling of the disease has identified few driver genes and in fact points to a balanced genomic pro...

Full description

Saved in:
Bibliographic Details
Main Authors: Mack, Stephen C. (Author) , Witt, Hendrik (Author) , Wang, Xin (Author) , Milde, Till (Author) , Yao, Yuan (Author) , Bertrand, Kelsey C. (Author) , Korshunov, Andrey (Author) , Pfister, Stefan (Author) , Taylor, Michael D. (Author)
Format: Article (Journal)
Language:English
Published: 25 February 2013
In: Brain pathology
Year: 2013, Volume: 23, Issue: 2, Pages: 206-209
ISSN:1750-3639
DOI:10.1111/bpa.12020
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/bpa.12020
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bpa.12020
Get full text
Author Notes:Stephen C. Mack, Hendrik Witt, Xin Wang, Till Milde, Yuan Yao, Kelsey C. Bertrand, Andrey Korshunov, Stefan M. Pfister, Michael D. Taylor
Description
Summary:Ependymoma is the third most common pediatric brain tumor, yet because of the paucity of effective therapeutic interventions, 45% of patients remain incurable. Recent transcriptional and copy number profiling of the disease has identified few driver genes and in fact points to a balanced genomic profile. Candidate gene approaches looking at hypermethylated promoters and genome-wide epigenetic arrays suggest that DNA methylation may be critical to ependymoma pathogenesis. This review attempts to highlight existing and emerging evidence implicating the ependymoma epigenome as a key player and that epigenetic modifiers may offer new targeted therapeutic avenues for patients.
Item Description:Gesehen am 11.06.2021
Physical Description:Online Resource
ISSN:1750-3639
DOI:10.1111/bpa.12020